High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis - Scorecard - MDSpire

High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis

  • By

  • Kristoffer Grundtvig Skaarup

  • Mats C. H. Lassen

  • Kaveh Hosseini

  • Niklas Dyrby Johansen

  • Matthew M. Loiacono

  • Rebecca C. Harris

  • Sandrine I. Samson

  • Arto A. Palmu

  • Kevin McConeghy

  • Stefan Gravenstein

  • Orly Vardeny

  • Brian Claggett

  • Scott D. Solomon

  • Federico Martinón-Torres

  • Tor Biering-Sørensen

  • May 26, 2026

  • 0 min

Share

Clinical Scorecard: Comparison of High-Dose and Standard-Dose Influenza Vaccines for Older Adults: A Meta-Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsRevise to include direct source attribution.
Target Population
Care Setting

Key Highlights

  • 0

Guideline-Based Recommendations

Diagnosis

    Management

    • R
    • e
    • v
    • i
    • s
    • e
    • t
    • o
    • i
    • n
    • c
    • l
    • u
    • d
    • e
    • d
    • i
    • r
    • e
    • c
    • t
    • s
    • o
    • u
    • r
    • c
    • e
    • a
    • t
    • t
    • r
    • i
    • b
    • u
    • t
    • i
    • o
    • n
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Revise to ensure all claims are supported by the source.

        Clinical Best Practices

        • 0

        Related Resources & Content

        Original Source(s)

        High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis

        • by Kristoffer Grundtvig Skaarup, Mats C. H. Lassen, Kaveh Hosseini, Niklas Dyrby Johansen, Matthew M. Loiacono, Rebecca C. Harris, Sandrine I. Samson, Arto A. Palmu, Kevin McConeghy, Stefan Gravenstein, Orly Vardeny, Brian Claggett, Scott D. Solomon, Federico Martinón-Torres, Tor Biering-Sørensen

        • May 26, 2026

        Related Content

        HPV vaccine hesitancy among Chinese adults and its influencing factors in the context of improved vaccine accessibility

        SARS-CoV-2 in Pregnancy—More Hints of Rare Complications

        The U.S. Government and Gavi, the Vaccine Alliance